Abstract:Endoscopic surveillance programs have been established to detect early neoplasia in Barrett's esophagus (BE) and during follow-up after endoscopic therapy to identify recurrent or residual lesions. The random biopsy protocol (RBP) is time-consuming, requires a large number of samples, and presents low adherence rates. To assess the yield of the RBP in detecting residual or recurrent lesions in patients under endoscopic surveillance after complete Barrett's eradication (CBE). Prospective review of endoscopic findings from all surveillance EGD's (Jun'10-Nov'10) after endotherapy for intramucosal carcinoma (IMC) or high-grade dysplasia (HGD). High definition white-light (HDE) and NBI exams were performed in all. Biopsy samples were taken at neo squamo-columnar junction (NSCJ) and from the neosquamous epithelium at 1-cm interval throughout the original involved segment. Any residual Barrett's areas were also biopsied. Endoscopic assessment at each sampled site was recorded. All pathology reports were reviewed and the presence of intestinal metaplasia (IM) was recorded. 19 patients (mean age 65.2 years, 89% men, long segment BE 73.7%) in endoscopic follow-up (median 14 months) after complete eradication (EMR=10,EMR+RFA=9) of BE (HGD=10,IMC=9) were included. Endoscopic evidence of residual BE (scattered islands=4,short segment=3) was noted in 7/19. Mucosa from tubular esophagus (TE) was sampled at 104 different sites (median per patient 4, mean 4.5), 86 at endoscopically normal mucosa and 18 at suspected BE. NSCJ was sampled in every patient,residual BE at NSCJ was endoscopically noted in 3/19. 338 specimens (median per patient 17, mean 17.8) were obtained: 248 from TE (normal squamous [NS] 195,suspected BE 53) and 90 from NSCJ (no identified lesions 81,suspected BE 9). At 84 (97.7%) of 86 sites from TE with no endoscopic evidence of BE, biopsies confirmed NS; IM was present only in 2 (1 LGD). No buried glands were reported. Global accuracy, sensitivity, specificity, positive predictive value and negative predictive value for the endoscopic evaluation of TE for detection of residual BE per sampled site were 88% (95% CI,0.80-0.96), 80% (95% CI,0.55-1.01), 89% (95% CI,0.83-0.96), 44% (95% CI,0.21-0.67) and 98% (95% CI,0.94-1.01) respectively, with a negative likelihood ratio of 0.22(95% CI,0.06-0.77). Biopsies at NSCJ revealed IM in 3/3 patients with residual BE (100%) at EGD and in 3/16 (23%) with no endoscopic evidence of BE. Endoscopic absence of IM in the TE of patients in surveillance after CBE is correlated with RB in up to 98% of cases; prediction by endoscopic evaluation was more challenging at the NSCJ. A careful approach with HDE+NBI may be developed in a protocolized setting to replace the RBP in the TE when BE is not endoscopically detected, but it still should be recommended at NSCJ.

A Prospective Multi-Center Study of a Bioabsorbable Biliary Wallstent (BAS) in 50 Patients with Malignant Obstructive Jaundice (MOJ)

Cryoablation of Swine Esophageal Mucosa: A Direct Comparison to Argon Plasma Coagulation (APC) and Multipolar Electrocoagulation (MPEC)

Sa1531 Endoscopic Surveillance after Complete Eradication of Barrett's Esophagus (BE): Do We Still Need Random Biopsies when There is No Endoscopic Evidence of Barrett's Epithelium?

Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management

Real-time diagnosis of Barrett's esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users

Multicenter, Prospective Trial Of Non-Endoscopic Biomarker-Driven Detection Of Barrett'S Esophagus And Esophageal Adenocarcinoma

Endoscopic Three-Dimensional Optical Coherence Tomography Confirms Squamous Epithelialization Following Radiofrequency Ablation For Barrett'S Esophagus

Computer-Simulated Biopsy Marking System for Endoscopic Surveillance of Gastric Lesions: A Pilot Study

Three-Dimensional Optical Coherence Tomography on Endoscopic Mucosal Resection Specimens Confirms Identification of Malignant from Metaplastic Lesions in Patients with Barrett's Esophagus

Computer-Aided Analysis of Gland-Like Subsurface Hyposcattering Structures in Barrett’s Esophagus Using Optical Coherence Tomography

Complete Endoscopic Mucosal Resection is Effective and Durable Treatment for Barrett's-associated Neoplasia.

Development of Advanced Imaging and Molecular Imaging for Barrett’s Neoplasia

Comprehensive imaging of gastroesophageal biopsy samples by spectrally encoded confocal microscopy

Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia

Markers Suggest Reduced Malignant Potential of Subsquamous Intestinal Metaplasia Compared with Barrett's Esophagus

Endoscopic diagnosis and surveillance of Barrett's esophagus

Probe-based endomicroscopy for in vivo detection of gastric intestinal metaplasia and neoplasia: a multicenter randomized controlled trial

New Classification of Gastric Pit Patterns and Vessel Architecture Using Probe-based Confocal Laser Endomicroscopy.

Multimodal endoscope can quantify wide-field fluorescence detection of Barrett's neoplasia.

Narrow-Band Imaging and White-Light Endoscopy with Optical Magnification in the Diagnosis of Dysplasia in Barrett'S Esophagus: Results of the Asia-Pacific Barrett'S Consortium

Short-segment Barrett’s Esophagus and Cardia Intestinal Metaplasia: A Comparative Analysis